Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 36936 | 70 | 33.7 | 68% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 8 | 4 | CARDIAC & CARDIOVASCULAR SYSTEM//PERIPHERAL VASCULAR DISEASES//CARDIOL | 1276458 |
| 131 | 3 | HEMATOLOGY//HAEMOPHILIA//TRANSFUSION | 66936 |
| 966 | 2 | CLOPIDOGREL//PRASUGREL//TICAGRELOR | 10690 |
| 36936 | 1 | CASE MIX GROUP CLASSIFICATION//CHARISMA TRIAL//ECON WORKING GRP | 70 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | CASE MIX GROUP CLASSIFICATION | authKW | 436224 | 1% | 100% | 1 |
| 2 | CHARISMA TRIAL | authKW | 436224 | 1% | 100% | 1 |
| 3 | ECON WORKING GRP | address | 436224 | 1% | 100% | 1 |
| 4 | EVIDENCE UNIT | address | 436224 | 1% | 100% | 1 |
| 5 | HEALTH ECONOMICS ANALYSES | authKW | 436224 | 1% | 100% | 1 |
| 6 | LOSSES OF CHANCES | authKW | 436224 | 1% | 100% | 1 |
| 7 | OCCLUSIVE VASCULAR EVENT OVE | authKW | 436224 | 1% | 100% | 1 |
| 8 | OUT PATIENT COSTS | authKW | 436224 | 1% | 100% | 1 |
| 9 | PHARMACODYNAMIC BIOEQUIVALENCE | authKW | 436224 | 1% | 100% | 1 |
| 10 | RANDOMIZED BLINDED TRIAL | authKW | 436224 | 1% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Health Policy & Services | 1697 | 26% | 0% | 18 |
| 2 | Health Care Sciences & Services | 1232 | 29% | 0% | 20 |
| 3 | Cardiac & Cardiovascular System | 320 | 27% | 0% | 19 |
| 4 | Economics | 227 | 20% | 0% | 14 |
| 5 | Medicine, General & Internal | 100 | 19% | 0% | 13 |
| 6 | Pharmacology & Pharmacy | 92 | 23% | 0% | 16 |
| 7 | Medicine, Research & Experimental | 41 | 10% | 0% | 7 |
| 8 | Medical Informatics | 34 | 3% | 0% | 2 |
| 9 | Law | 13 | 3% | 0% | 2 |
| 10 | Peripheral Vascular Diseases | 10 | 4% | 0% | 3 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | ECON WORKING GRP | 436224 | 1% | 100% | 1 |
| 2 | EVIDENCE UNIT | 436224 | 1% | 100% | 1 |
| 3 | SOZIAL PRAVANT MED | 436224 | 1% | 100% | 1 |
| 4 | UNIT PREVENT PERIPHERAL VASC DIS | 436224 | 1% | 100% | 1 |
| 5 | HLTH SYST PERFORMANCE | 109055 | 1% | 25% | 1 |
| 6 | BARNET CHASE FARM NHS TRUST | 87243 | 1% | 20% | 1 |
| 7 | CLIN ACCESS REDESIGN UNIT | 87243 | 1% | 20% | 1 |
| 8 | ADELAIDE HLTH SERV | 72702 | 1% | 17% | 1 |
| 9 | HLTH OUTCOMES POLICY ECON | 62316 | 1% | 14% | 1 |
| 10 | NEUROL CLIN POLICLIN | 48468 | 1% | 11% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | PHARMACOECONOMICS | 12697 | 11% | 0% | 8 |
| 2 | JOURNAL OF INTELLECTUAL PROPERTY RIGHTS | 4689 | 1% | 1% | 1 |
| 3 | AUSTRALIAN HEALTH REVIEW | 4685 | 4% | 0% | 3 |
| 4 | EUROPEAN JOURNAL OF HEALTH ECONOMICS | 2577 | 3% | 0% | 2 |
| 5 | IIC-INTERNATIONAL REVIEW OF INDUSTRIAL PROPERTY AND COPYRIGHT LAW | 2534 | 1% | 1% | 1 |
| 6 | VALUE IN HEALTH | 2520 | 4% | 0% | 3 |
| 7 | CURRENT MEDICAL RESEARCH AND OPINION | 2447 | 7% | 0% | 5 |
| 8 | NATURE REVIEWS CARDIOLOGY | 1024 | 1% | 0% | 1 |
| 9 | GLOBALIZATION AND HEALTH | 994 | 1% | 0% | 1 |
| 10 | MEDICAL DECISION MAKING | 976 | 3% | 0% | 2 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | GOLDMAN, L , GASPOZ, JM , (2008) COST-EFFECTIVENESS OF CLOPIDOGREL: SEEING THROUGH THE SMOKE.MEDICAL DECISION MAKING. VOL. 28. ISSUE 6. P. 803-809 | 21 | 60% | 2 |
| 2 | BRAMKAMP, M , SZUCS, TD , (2008) PHARMACOECONOMIC EVALUATION OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES. LONG-TERM TREATMENT, SECONDARY PROPHYLAXIS, AND PERCUTANEOUS CORONARY INTERVENTION.HERZ. VOL. 33. ISSUE 1. P. 60-70 | 14 | 52% | 1 |
| 3 | KESSLER, C , THOMAS, K , KAO, J , (2012) ANTIPLATELET THERAPY FOR SECONDARY PREVENTION OF ACUTE CORONARY SYNDROME, TRANSIENT ISCHEMIC ATTACK, AND NONCARDIOEMBOLIC STROKE IN AN ERA OF COST CONTAINMENT.JOURNAL OF INVESTIGATIVE MEDICINE. VOL. 60. ISSUE 5. P. 792 -800 | 17 | 31% | 0 |
| 4 | ARNOLD, SV , COHEN, DJ , MAGNUSON, EA , (2011) COST-EFFECTIVENESS OF ORAL ANTIPLATELET AGENTS-CURRENT AND FUTURE PERSPECTIVES.NATURE REVIEWS CARDIOLOGY. VOL. 8. ISSUE 10. P. 580 -591 | 16 | 31% | 6 |
| 5 | HEEG, B , DAMEN, J , VAN HOUT, B , (2007) ORAL ANTIPLATELET THERAPY IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS - AN ASSESSMENT FROM THE PAYER'S PERSPECTIVE.PHARMACOECONOMICS. VOL. 25. ISSUE 12. P. 1063-1082 | 16 | 33% | 13 |
| 6 | CHENG, JW , (2007) PHARMACOECONOMIC ANALYSIS OF CLOPIDOGREL IN SECONDARY PREVENTION OF CORONARY ARTERY DISEASE.JOURNAL OF MANAGED CARE PHARMACY. VOL. 13. ISSUE 4. P. 326 -336 | 13 | 38% | 11 |
| 7 | CUI, M , TU, CC , CHEN, EZ , WANG, XL , TAN, SC , CHEN, C , (2016) A COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL FOR PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME IN CHINA.ADVANCES IN THERAPY. VOL. 33. ISSUE 9. P. 1600 -1611 | 6 | 67% | 0 |
| 8 | WEINTRAUB, WS , MANDEL, L , WEISS, SA , (2013) ANTIPLATELET THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: ECONOMIC CONSIDERATIONS.PHARMACOECONOMICS. VOL. 31. ISSUE 11. P. 959-970 | 17 | 24% | 2 |
| 9 | CHEN, J , SHI, CX , MAHONEY, EM , DUNN, ES , RINFRET, S , CARO, JJ , O'BRIEN, J , EL-HADI, W , BHATT, DL , TOPOL, EJ , ET AL (2011) ECONOMIC EVALUATION OF CLOPIDOGREL PLUS ASPIRIN FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN CANADA FOR PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE: RESULTS FROM THE CHARISMA TRIAL.CANADIAN JOURNAL OF CARDIOLOGY. VOL. 27. ISSUE 2. P. 222 -231 | 11 | 34% | 1 |
| 10 | GIALAMA, F , MILONI, E , MANIADAKIS, N , (2014) COST EFFECTIVENESS OF TREATMENTS FOR NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME.PHARMACOECONOMICS. VOL. 32. ISSUE 11. P. 1063 -1078 | 11 | 22% | 0 |
Classes with closest relation at Level 1 |